difference between prevention and prophylaxis
Alternative Names: RN-0191Latest Information Update: 23 Jul 2024
At a glance
- Originator Ikaria Bioscience
- Class Antihyperlipidaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypercholesterolaemia
Most Recent Events
- 19 Jul 2024 Rona Therapeutics completes phase I trial in Hypercholesterolemia (In volunteers) in China (SC) (NCT06132360)
- 19 Jul 2024 Rona Therapeutics completes phase I trial in Hyperlipidaemia (In volunteers) in Australia (SC) (NCT05905068)
- 19 Jul 2024 Rona Therapeutics plans a phase II trial for Hypercholesterolemia